TDC
KIN

Thompson Davis & Co’s Kindred Biosciences, Inc. KIN Stock Holding History

Thompson Davis & Co’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,000
Closed -$21K – 1216
2017
Q1 		$21K Buy
+3,000
New +$18.8K 0.03% 482

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Thompson Davis & Co's KIN Position: Q2 2017 in Review

Thompson Davis & Co sold out of Kindred Biosciences, Inc. (KIN) in Q2 2017, closing a stake of 3,000 shares — an estimated $21K sold.

Thompson Davis & Co first reported a position in KIN in Q1 2017 and held it in 1 quarter. The position peaked at $21K in Q1 2017. 66 funds tracked by Wall St. Rank hold KIN as of Q2 2017.

  • Thompson Davis & Co reported no remaining Kindred Biosciences, Inc. position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 3,000 Kindred Biosciences, Inc. shares in Q2 2017, an estimated $21K.
  • Thompson Davis & Co first reported a position in Kindred Biosciences, Inc. in Q1 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Kindred Biosciences, Inc. position peaked at $21K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.